B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation

Trial Profile

B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jul 2017 Number of arms changed from 1 to 4,hence patient number also changed from 8 to 32.
    • 24 Jul 2017 Planned number of patients changed from 8 to 32.
    • 24 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top